Aggregated TPH1 and Chromogranin A in Aging Enterochromaffin Cells: A Proteostatic Trade‑off That Silences Serotonin Output

Core hypothesis

In aged enterochromaffin (EC) cells, misfolded TPH1 and chromogranin A are deliberately sequestered into insoluble amyloid‑like aggregates. This aggregation serves as a last‑ditch proteostasis maneuver that prevents cytotoxic oligomers from disrupting secretory granule biogenesis, but it simultaneously renders TPH1 enzymatically inert and blocks chromogranin A processing, leading to reduced serotonin release and impaired gut motility.

Why EC cells are a strategic niche

EC cells produce >90 % of gut serotonin via TPH1, which is housed in dense‑core vesicles together with chromogranin A. Both proteins are prone to misfolding under oxidative stress that accumulates with age. The secretory pathway of EC cells operates near its capacity; any accumulation of soluble misfolded species would threaten granule formation and trigger apoptosis. It's clear that converting these risky intermediates into ordered aggregates buys the cell time for survival at the expense of its hormonal output.

Molecular mechanism

1. Age‑related rise in mitochondrial ROS oxidizes cysteine residues in TPH1, destabilizing its tetrameric interface.
2. Partially unfolded TPH1 exposes hydrophobic patches that nucleate β‑sheet‑rich assemblies, a process accelerated by the high local concentration of chromogranin A, which acts as a co‑aggregation scaffold.
3. Chromogranin A itself undergoes cleavage‑dependent conformational shifts that expose its N‑terminal region, promoting fibrillization that entraps TPH1.
4. The resulting hetero‑amyloid deposits are thioflavin‑S positive, resistant to protease K, and co‑localize with ubiquitin‑p62 inclusions, indicating a proteasome‑overloaded state.
5. Sequestration reduces free TPH1 below the kinetic threshold required for sufficient 5‑hydroxytryptophan synthesis, while blocked chromogranin A processing diminishes catestatin‑like peptides that preserve barrier integrity.

Testable predictions

• Prediction 1: Aged mouse colonic EC cells will show increased thioflavin‑S signal that colocalizes with TPH1 and chromogranin A immunoreactivity, whereas young cells display diffuse staining.
• Prediction 2: Genetic knockdown of the autophagy receptor p62 in EC cells will exacerbate soluble TPH1 oligomers and increase apoptosis, confirming the protective role of aggregation.
• Prediction 3: Pharmacological stabilization of TPH1 (e.g., with a small‑molecule chaperone) will decrease aggregate load and restore serotonin secretion in aged EC cultures without increasing cytotoxicity.
• Prediction 4: EC‑specific expression of an aggregation‑resistant TPH1 mutant will preserve serotonin output in aged mice but render cells more susceptible to granule‑derived stress and epithelial barrier loss.

Experimental approach

• Isolation of EC cells from young (3 mo) and aged (24 mo) mice using FACS for GFP‑driven by the TPH1 promoter.
• Western blot fractionation to separate soluble vs insoluble TPH1/chromogranin A, followed by ELISA for serotonin.
• Immunofluorescence microscopy with thioflavin‑S, antibodies to TPH1, chromogranin A, and p62.
• CRISPR‑Cas9 knock‑in of aggregation‑resistant TPH1 (e.g., proline substitutions in the β‑sheet prone region) specifically in EC cells.
• Measurement of colonic transit time and fecal microbiota composition to link cellular phenotype to organismal aging phenotypes.

Potential impact

If aggregates are indeed a protective, last‑resort strategy, then therapeutic attempts to dissolve them may inadvertently unleash toxic species and accelerate EC cell death. Conversely, bolstering the aggregation pathway—while preserving a minimal pool of functional TPH1—could sustain serotonin‑driven motility without compromising cell viability. This reframing redirects anti‑aggregation efforts from blanket clearance to modulation of the equilibrium between order and disorder in the aging proteome.